Oncoheroes
Founded Year
2018Stage
Seed VC | AliveTotal Raised
$1.21MLast Raised
$1.21M | 3 yrs agoOncoheroes's Products & Differentiation
See Oncoheroes's products and how their products differentiate from alternatives and competitors
volasertib
Volasertib is a highly potent Polo-like kinase 1 (PLK-1) inhibitor. PLK-1 is a key regulator of the cell cycle, is over-expressed in many cancers, and has been associated with poor survival. Volasertib has been studied as a single agent in Phase I in children with leukemia and refractory solid tumors. Oncoheroes is currently planning the clinical evaluation of volasertib in RMS in collaboration with international pediatric oncology networks. Clinical studies are expected to be launched in 2022. Volasertib received Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from the United States Food and Drug Administration (FDA) in 2020. RPDD qualifies Oncoheroes to receive fast track review, and a priority review voucher (PRV) at the time of marketing approval of volasertib.
Subscribe to see more
We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.
Subscribe to see more
We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.
Expert Collections containing Oncoheroes
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Oncoheroes is included in 2 Expert Collections, including Biopharma Tech.
Biopharma Tech
5,241 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Cancer
3,605 items
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
Latest Oncoheroes News
Jan 4, 2022
Privately-held Oncoheroes Biosciences is to acquire certain development rights to Allarity Therapeutics’… To continue reading The Pharma Letter please login , subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space. Or, if you're only interested in reading the content about a specific topic (M&A, coronavirus/COVID-19, pricing, reimbursement and access, outsourcing, CRO and CMO, and regulation), then you can take our £10 per month channel subscription offer, which gives you access to all our news articles and in-depth content on this subject.
Oncoheroes Web Traffic
Oncoheroes Rank
When was Oncoheroes founded?
Oncoheroes was founded in 2018.
Where is Oncoheroes's headquarters?
Oncoheroes's headquarters is located at 43 Kent Street, Brookline.
What is Oncoheroes's latest funding round?
Oncoheroes's latest funding round is Seed VC.
How much did Oncoheroes raise?
Oncoheroes raised a total of $1.21M.
Who are the investors of Oncoheroes?
Investors of Oncoheroes include Dreamers Fund.
Who are Oncoheroes's competitors?
Competitors of Oncoheroes include Day One Biopharmaceuticals.
What products does Oncoheroes offer?
Oncoheroes's products include volasertib and 2 more.
You May Also Like
Day One Biopharmaceuticals (NASDAQ: DAWN) finds and develops new therapies that meet the critical needs of people living with cancer.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.